nach oben

Erschienen in:

23.01.2016 | Original Article

Tumour-suppressive role of PTPN13 in hepatocellular carcinoma and its clinical significance

verfasst von: Hao Zhan, Jiahao Jiang, Chubin Luo, Qiman Sun, Aiwu Ke, Chao Sun, Jinwu Hu, Zhiqiang Hu, Bo Hu, Kai Zhu, Jia Fan, Jian Zhou, Xiaowu Huang

Erschienen in: Tumor Biology | Ausgabe 7/2016

Einloggen, um Zugang zu erhalten

Abstract

Hepatocellular carcinoma (HCC) is the second leading cause of cancer mortality and carries a dismal prognosis. The present study aimed to identify the tumour-suppressive role and clinical implications of PTPN13 in HCC progression. We tested the effects of PTPN13 expression in proliferation, invasion, epithelial–mesenchymal transition and associated pathways in HCC cell lines in vitro. Furthermore, its clinical relevance was evaluated in a tissue microarray analysis of samples from 282 HCC patients. Various HCC cell lines expressed relatively low PTPN13 protein levels in vitro. PTPN13 overexpression significantly inhibited the progression of HCC cells, possibly by inhibiting epithelial–mesenchymal transition through inactivation of the EGFR/ERK signalling pathway. Tissue microarray analysis revealed that high PTPN13 expression was correlated with a favourable prognosis in postoperative HCC patients. This study demonstrated the tumour suppressor, PTPN13, as an alternative therapeutic target for HCC.

Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA: Cancer J Clin. 2015;65(2):87–108.

El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118–27.CrossRefPubMed

Maluccio M, Covey A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA: Cancer J Clin. 2012;62:394–9.

Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010;141:1117–34.CrossRefPubMedPubMedCentral

Julien SG, Dube N, Hardy S, Tremblay ML. Inside the human cancer tyrosine phosphatome. Nat Rev Cancer. 2011;11:35–49.CrossRefPubMed

Gao Q, Zhao YJ, Wang XY, et al. Activating mutations in PTPN3 promote cholangiocarcinoma cell proliferation and migration and are associated with tumor recurrence in patients. Gastroenterology. 2014;146:1397–407.CrossRefPubMed

Chan G, Kalaitzidis D, Neel BG. The tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer Metastasis Rev. 2008;27:179–92.CrossRefPubMed

Zbuk KM, Eng C. Cancer phenomics: RET and PTEN as illustrative models. Nat Rev Cancer. 2007;7:35–45.CrossRefPubMed

Yeh SH, Wu DC, Tsai CY, et al. Genetic characterization of Fas-associated phosphatase-1 as a putative tumor suppressor gene on chromosome 4q21.3 in hepatocellular carcinoma. Clin Cancer Res. 2006;12:1097–108.CrossRefPubMed

10.

Wang Z, Shen D, Parsons DW, et al. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Sci N Y. 2004;304:1164–6.CrossRef

11.

Zhu JH, Chen R, Yi W, et al. Protein tyrosine phosphatase PTPN13 negatively regulates Her2/ErbB2 malignant signaling. Oncogene. 2008;27:2525–31.CrossRefPubMed

12.

Sotelo NS, Schepens JT, Valiente M, et al. PTEN-PDZ domain interactions: binding of PTEN to PDZ domains of PTPN13. Methods. 2015;77–78:147–56.CrossRefPubMed

13.

Freiss G, Chalbos D. PTPN13/PTPL1: an important regulator of tumor aggressiveness. Anti Cancer Agents Med Chem. 2011;11:78–88.CrossRef

14.

Sun HC, Zhang W, Qin LX, et al. Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma. J Hepatol. 2007;47:684–90.CrossRefPubMed

15.

Gao Q, Wang XY, Qiu SJ, et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res: Off J Am Assoc Cancer Res. 2009;15:971–9.CrossRef

16.

Zhou SL, Dai Z, Zhou ZJ, et al. Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma. Hepatol Baltimo, Md. 2012;56:2242–54.CrossRef

17.

Wang J, Ren J, Wu B, et al. Activation of Rab8 guanine nucleotide exchange factor Rabin8 by ERK1/2 in response to EGF signaling. Proc Natl Acad Sci U S A. 2015;112:148–53.CrossRefPubMed

18.

Hunter T. Tyrosine phosphorylation: thirty years and counting. Curr Opin Cell Biol. 2009;21:140–6.CrossRefPubMedPubMedCentral

19.

Abaan OD, Toretsky JA. PTPL1: a large phosphatase with a split personality. Cancer Metastasis Rev. 2008;27:205–14.CrossRefPubMedPubMedCentral

20.

Erdmann KS. The protein tyrosine phosphatase PTP-basophil/basophil-like. Eur J Biochem. 2003;270:4789–98.CrossRefPubMed

21.

Ying J, Li H, Cui Y, et al. Epigenetic disruption of two proapoptotic genes MAPK10/JNK3 and PTPN13/FAP-1 in multiple lymphomas and carcinomas through hypermethylation of a common bidirectional promoter. Leukemia. 2006;20:1173–5.CrossRefPubMed

22.

Lucci MA, Orlandi R, Triulzi T, et al. Expression profile of tyrosine phosphatases in HER2 breast cancer cells and tumors. Cell Oncol. 2010;32:361–72.PubMedPubMedCentral

23.

Wieckowski E, Atarashi Y, Stanson J, et al. FAP-1-mediated activation of NF-kappaB induces resistance of head and neck cancer to Fas-induced apoptosis. J Cell Biochem. 2007;100:16–28.CrossRefPubMed

24.

Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119:1420–8.CrossRefPubMedPubMedCentral

25.

Castilla C, Chinchon D, Medina R, et al. PTPL1 and PKCdelta contribute to proapoptotic signalling in prostate cancer cells. Cell Death Dis. 2013;4:e576.CrossRefPubMedPubMedCentral

26.

Castilla C, Flores ML, Conde JM, et al. Downregulation of protein tyrosine phosphatase PTPL1 alters cell cycle and upregulates invasion-related genes in prostate cancer cells. Clin Exp Metastasis. 2012;29:349–58.CrossRefPubMed

27.

Scrima M, De Marco C, De Vita F, et al. The nonreceptor-type tyrosine phosphatase PTPN13 is a tumor suppressor gene in non-small cell lung cancer. Am J Pathol. 2012;180:1202–14.CrossRefPubMed

28.

Glondu-Lassis M, Dromard M, Lacroix-Triki M, et al. PTPL1/PTPN13 regulates breast cancer cell aggressiveness through direct inactivation of Src kinase. Cancer Res. 2010;70:5116–26.CrossRefPubMedPubMedCentral

29.

Revillion F, Puech C, Rabenoelina F, et al. Expression of the putative tumor suppressor gene PTPN13/PTPL1 is an independent prognostic marker for overall survival in breast cancer. Int J Cancer. 2009;124:638–43.CrossRefPubMedPubMedCentral

30.

Dromard M, Bompard G, Glondu-Lassis M, et al. The putative tumor suppressor gene PTPN13/PTPL1 induces apoptosis through insulin receptor substrate-1 dephosphorylation. Cancer Res. 2007;67:6806–13.CrossRefPubMed

31.

Kawano S, Ikeda W, Kishimoto M, et al. Silencing of ErbB3/ErbB2 signaling by immunoglobulin-like Necl-2. J Biol Chem. 2009;284:23793–805.CrossRefPubMedPubMedCentral

32.

Schickel R, Park SM, Murmann AE, Peter ME. miR-200c regulates induction of apoptosis through CD95 by targeting FAP-1. Mol Cell. 2010;38:908–15.CrossRefPubMedPubMedCentral

33.

Gloire G, Charlier E, Piette J. Regulation of CD95/APO-1/Fas-induced apoptosis by protein phosphatases. Biochem Pharmacol. 2008;76:1451–8.CrossRefPubMed

34.

Winterhoff BJ, Arlt A, Duttmann A, et al. Characterisation of FAP-1 expression and CD95 mediated apoptosis in the A818-6 pancreatic adenocarcinoma differentiation system. Differentiation. 2012;83:148–57.CrossRefPubMed

35.

Cuppen E, Nagata S, Wieringa B, Hendriks W. No evidence for involvement of mouse protein-tyrosine phosphatase-BAS-like Fas-associated phosphatase-1 in Fas-mediated apoptosis. J Biol Chem. 1997;272:30215–20.CrossRefPubMed

Titel: Tumour-suppressive role of PTPN13 in hepatocellular carcinoma and its clinical significance
verfasst von: Hao Zhan
Jiahao Jiang
Chubin Luo
Qiman Sun
Aiwu Ke
Chao Sun
Jinwu Hu
Zhiqiang Hu
Bo Hu
Kai Zhu
Jia Fan
Jian Zhou
Xiaowu Huang
Publikationsdatum: 23.01.2016
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 7/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-016-4843-2

Springer Medizin

Tumour-suppressive role of PTPN13 in hepatocellular carcinoma and its clinical significance

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2016

Biological characteristics of a novel giant cell tumor cell line derived from spine

Decreased CK1δ expression predicts prolonged survival in colorectal cancer patients

MiR-145 promotes TNF-α-induced apoptosis by facilitating the formation of RIP1-FADDcaspase-8 complex in triple-negative breast cancer

MiR-381 inhibits epithelial ovarian cancer malignancy via YY1 suppression

CAF cellular glycolysis: linking cancer cells with the microenvironment

TIMP3 regulates osteosarcoma cell migration, invasion, and chemotherapeutic resistances

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie